<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Fuche FJ</submitter><funding>NIAID NIH HHS</funding><pagination>1427-1435</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6663134</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(6)</volume><pubmed_abstract>Non-typhoidal &lt;i>Salmonella&lt;/i> (NTS) are a leading cause of foodborne infections worldwide, and serogroups B, C&lt;sub>1&lt;/sub>, C&lt;sub>2-&lt;/sub>C&lt;sub>3&lt;/sub> and D are the most common serogroups associated with human disease. While live vaccine candidates that protect against &lt;i>S.&lt;/i> Typhimurium (serogroup B) and &lt;i>S.&lt;/i> Enteritidis (serogroup D) have been described by us and others, far less effort has been directed towards vaccines that target either serogroup C&lt;sub>1&lt;/sub> or C&lt;sub>2-&lt;/sub>C&lt;sub>3&lt;/sub> &lt;i>Salmonella&lt;/i>. Here we describe a &lt;i>Salmonella&lt;/i> Newport-based live-attenuated vaccine (serogroup C&lt;sub>2-&lt;/sub>C&lt;sub>3&lt;/sub>). Deletion of the genes &lt;i>clpX&lt;/i> or &lt;i>rfaL&lt;/i>, previously used in live vaccines to attenuate &lt;i>S.&lt;/i> Typhimurium and/or &lt;i>S.&lt;/i> Enteritidis, faile</pubmed_abstract><journal>Human vaccines &amp; immunotherapeutics</journal><pubmed_title>Deletions in &lt;i>guaBA&lt;/i> and &lt;i>htrA&lt;/i> but not &lt;i>clpX&lt;/i> or &lt;i>rfaL&lt;/i> constitute a live-attenuated vaccine strain of &lt;i>Salmonella&lt;/i> Newport to protect against serogroup C&lt;sub>2-&lt;/sub>C&lt;sub>3&lt;/sub> &lt;i>Salmonella&lt;/i> in mice.</pubmed_title><pmcid>PMC6663134</pmcid><funding_grant_id>U19 AI109776</funding_grant_id><pubmed_authors>Fuche FJ</pubmed_authors><pubmed_authors>Ramachandran G</pubmed_authors><pubmed_authors>Jones JA</pubmed_authors><pubmed_authors>Tennant SM</pubmed_authors><pubmed_authors>Higginson EE</pubmed_authors><pubmed_authors>Simon R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Deletions in &lt;i>guaBA&lt;/i> and &lt;i>htrA&lt;/i> but not &lt;i>clpX&lt;/i> or &lt;i>rfaL&lt;/i> constitute a live-attenuated vaccine strain of &lt;i>Salmonella&lt;/i> Newport to protect against serogroup C&lt;sub>2-&lt;/sub>C&lt;sub>3&lt;/sub> &lt;i>Salmonella&lt;/i> in mice.</name><description>Non-typhoidal &lt;i>Salmonella&lt;/i> (NTS) are a leading cause of foodborne infections worldwide, and serogroups B, C&lt;sub>1&lt;/sub>, C&lt;sub>2-&lt;/sub>C&lt;sub>3&lt;/sub> and D are the most common serogroups associated with human disease. While live vaccine candidates that protect against &lt;i>S.&lt;/i> Typhimurium (serogroup B) and &lt;i>S.&lt;/i> Enteritidis (serogroup D) have been described by us and others, far less effort has been directed towards vaccines that target either serogroup C&lt;sub>1&lt;/sub> or C&lt;sub>2-&lt;/sub>C&lt;sub>3&lt;/sub> &lt;i>Salmonella&lt;/i>. Here we describe a &lt;i>Salmonella&lt;/i> Newport-based live-attenuated vaccine (serogroup C&lt;sub>2-&lt;/sub>C&lt;sub>3&lt;/sub>). Deletion of the genes &lt;i>clpX&lt;/i> or &lt;i>rfaL&lt;/i>, previously used in live vaccines to attenuate &lt;i>S.&lt;/i> Typhimurium and/or &lt;i>S.&lt;/i> Enteritidis, faile</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019</publication><modification>2025-04-04T11:43:12.057Z</modification><creation>2019-08-09T07:03:55Z</creation></dates><accession>S-EPMC6663134</accession><cross_references><pubmed>29927725</pubmed><doi>10.1080/21645515.2018.1491499</doi></cross_references></HashMap>